Advancements and future directions in transformative therapies of prostate cancer
- 1Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China
Abstract
The treatment landscape for advanced prostate cancer (PCa) has significantly evolved in recent years, marked by the introduction of several novel therapies. Targeting the androgen receptor (AR) remains a cornerstone of treatment, with drugs, such as abiraterone and next-generation antiandrogens, providing substantial benefits. Poly (ADP-ribose) polymerase (PARP) inhibitors, both as monotherapies and in combination with other agents, have demonstrated promise, particularly for patients with deoxyribonucleic acid (DNA) repair defects. While immunotherapy has historically shown limited efficacy in the treatment of PCa, recent findings from the CONTACT‑2 study suggest a potential breakthrough, demonstrating improved patient outcomes with the combined use of atezolizumab and cabozantinib. Additionally, emerging therapies targeting cyclin-dependent kinases 4 and 6 (CDK4/6), the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway, and epigenetic modifications offer new treatment possibilities. These advancements, coupled with ongoing research into combination therapies and novel drug targets, hold the potential to further enhance outcomes for patients with advanced PCa. This article review summarizes the latest transformative therapies in PCa care.
Related
- Prostate cancer: advancements in targeted therapies
- Bipolar androgen therapy in castration-resistant prostate cancer: Biological rationale, clinical evidence, and future directions.
- Neuromodulation Therapies for Depression: Current Status and Future Directions
- Transoral Robotic Surgery in Head and Neck Oncology: A Scoping Review of Evidence, Technological Advancements, and Future Trajectories
- Oral Targeted Therapies and Clinician Comanagement Among Men With Advanced Prostate Cancer
BibTeX
@article{zhao2026advancements,
title = {{Advancements and future directions in transformative therapies of prostate cancer}},
author = {Jinge Zhao and Bo Tang and Hao Zeng and Qiang Wei},
journal = {Chinese Medical Journal},
year = {2026},
month = sep,
doi = {10.1097/cm9.0000000000004322},
url = {https://doi.org/10.1097/cm9.0000000000004322},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Advancements and future directions in transformative therapies of prostate cancer
AU - Jinge Zhao
AU - Bo Tang
AU - Hao Zeng
AU - Qiang Wei
PY - 2026
DA - 2026/09/18
JO - Chinese Medical Journal
DO - 10.1097/cm9.0000000000004322
UR - https://doi.org/10.1097/cm9.0000000000004322
AB - The treatment landscape for advanced prostate cancer (PCa) has significantly evolved in recent years, marked by the introduction of several novel therapies. Targeting the androgen receptor (AR) remains a cornerstone of treatment, with drugs, such as abiraterone and next-generation antiandrogens, providing substantial benefits. Poly (ADP-ribose) polymerase (PARP) inhibitors, both as monotherapies and in combination with other agents, have demonstrated promise, particularly for patients with deoxyribonucleic acid (DNA) repair defects. While immunotherapy has historically shown limited efficacy in the treatment of PCa, recent findings from the CONTACT‑2 study suggest a potential breakthrough, demonstrating improved patient outcomes with the combined use of atezolizumab and cabozantinib. Additionally, emerging therapies targeting cyclin-dependent kinases 4 and 6 (CDK4/6), the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway, and epigenetic modifications offer new treatment possibilities. These advancements, coupled with ongoing research into combination therapies and novel drug targets, hold the potential to further enhance outcomes for patients with advanced PCa. This article review summarizes the latest transformative therapies in PCa care.
SN - 0366-6999
SN - 2542-5641
ER -